following an abbreviated submission:
empagliflozin (Jardiance®) is accepted for use within NHSScotland.
Indication under review: in adults for the treatment of symptomatic chronic heart failure with reduced ejection fraction.
Empagliflozin offers an additional treatment choice in the therapeutic class of sodium glucose co-transporter 2 inhibitors in this indication.
Download detailed advice622KB (PDF)
- Medicine name:
- empagliflozin (Jardiance)
- SMC ID:
In adults for treatment of symptomatic chronic heart failure with reduced ejection fraction.
- Pharmaceutical company
- Boehringer Ingelheim Ltd
- BNF chapter
- Cardiovascular system
- Submission type
- Date advice published
- 11 October 2021